SCHEMBL25836510

SCHEMBL25836510

CC(C)NCCOCCNC(=O)CCOCCNC(=O)C(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
KDM4E B2RXH2 4/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2C19 P33261 2/20 0.37
CYP1A2 P05177 1/20 0.37
POLB P06746 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.34
ADRB2 P07550 4/20 0.34
ADRB1 P08588 4/20 0.34
GLP1R P43220 5/20 0.33
CA12 O43570 2/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA4 P22748 2/20 0.33
CA9 Q16790 2/20 0.33
CA14 Q9ULX7 2/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22837695 0.90 KMT2A (0.58) KMT2AMEN1KDM4ECYP2D6CYP2C19
SCHEMBL21106234 0.89 KMT2A (0.61) KMT2AMEN1KDM4ECYP2D6CYP2C19
SCHEMBL18908752 0.89 KMT2A (0.61) KMT2AMEN1KDM4ECYP2D6CYP2C19
SCHEMBL21106165 0.89 KMT2A (0.61) KMT2AMEN1KDM4ECYP2D6CYP2C19
SCHEMBL18908759 0.89 KMT2A (0.61) KMT2AMEN1KDM4ECYP2D6CYP2C19
SCHEMBL25834730 0.89 KMT2A (0.61) KMT2AMEN1KDM4ECYP2D6CYP2C19
SCHEMBL26034118 0.88 MEN1 (0.41) KMT2AMEN1KDM4ECYP2D6CYP2C19
SCHEMBL25836541 0.86 MEN1 (0.42) KMT2AMEN1KDM4ECYP2D6CYP2C19
SCHEMBL20073434 0.85 MEN1 (0.47) KMT2AMEN1ALDH1A1TSHRADRB2
SCHEMBL24297138 0.84 MEN1 (0.53) KMT2AMEN1ALDH1A1TSHRGLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 KMT2A 1603/4885MEN1 4753/4885KDM4E 1852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.